Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial | Zendy

Opeolu Adeoye | Zendy; Heidi Sucharew | Zendy; Jane Khoury | Zendy; Achala Vagal | Zendy; Pamela Schmit | Zendy; Irene Ewing | Zendy; Steven R. Levine | Zendy; Stacie L Demel | Zendy; Bryan Eckerle | Zendy; Brian Katz | Zendy; Dawn Kleindorfer | Zendy; Brian Stettler | Zendy; Daniel Woo | Zendy; Pooja Khatri | Zendy; Joseph P. Broderick | Zendy; Arthur Pancioli | Zendy

Open Access

Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial

Author(s) -

Opeolu Adeoye,

Heidi Sucharew,

Jane Khoury,

Achala Vagal,

Pamela Schmit,

Irene Ewing,

Steven R. Levine,

Stacie L Demel,

Bryan Eckerle,

Brian Katz,

Dawn Kleindorfer,

Brian Stettler,

Daniel Woo,

Pooja Khatri,

Joseph P. Broderick,

Arthur Pancioli

Publication year - 2015

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.115.010260

Subject(s) - medicine , eptifibatide , interquartile range , regimen , thrombolysis , stroke (engine) , fibrinolytic agent , tissue plasminogen activator , surgery , myocardial infarction , percutaneous coronary intervention , mechanical engineering , engineering

The Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator (r-tPA; CLEAR) in Acute Ischemic Stroke (AIS) and CLEAR-Enhanced Regimen (CLEAR-ER) trials demonstrated safety of reduced dose r-tPA plus the glycoprotein 2b/3a inhibitor, eptifibatide, in AIS compared with r-tPA alone. The objective of the CLEAR-Full Dose Regimen (CLEAR-FDR) trial was to estimate the rate of symptomatic intracerebral hemorrhage (sICH) in AIS patients treated with the combination of full-dose r-tPA plus eptifibatide.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research